Home / Market News / $MXCT

$MXCT news and market catalysts

The 5 most recent market catalysts affecting $MXCT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

5 catalysts 0 high impact 4 bullish 0 bearish Biotechnology
Nov 3, 2026 Corporate Catalyst Neutral Impact 55
Liontrust Investment Partners Discloses 4.9% Stake in MaxCyte, Inc.
Liontrust Investment Partners has filed a Schedule 13D, revealing a 4.9% ownership stake in MaxCyte, Inc. This disclosure is significant as it indicates a substantial institutional…
Oct 14, 2026 Market Technicals Bullish Impact 55
12 Health Care Stocks Moving In Wednesday's Intraday Session
This filing is not an 8-K in the traditional sense, but rather a news report from Benzinga's automated content engine summarizing intraday stock performance for a selection of heal…
Oct 14, 2026 Corporate Catalyst Bullish Impact 75
MaxCyte Reports Preliminary Q3 Core Revenue Of ~$8.1M, Up 26% YoY; Raises FY26 Revenue Guidance To ~$34M, Core Business Revenue Outlook To ~$28M
MaxCyte announced preliminary Q3 2026 core business revenue of $8.1 million, representing a robust 26% year-over-year growth. This strong performance has led the company to raise i…
Aug 12, 2026 Corporate Catalyst Bullish Impact 75
MaxCyte Q2 EPS $(0.08) Beats $(0.09) Estimate, Sales $7.271M Beat $6.475M Estimate
MaxCyte's Q2 earnings report showed a smaller loss per share than anticipated and sales that exceeded analyst consensus. This indicates better-than-expected operational performance…
Jul 21, 2026 Corporate Catalyst Bullish Impact 65
MaxCyte Enters Into Technology License Partnership With Genentech To Support Development Of Cell Therapy Programs
MaxCyte announced a technology license partnership with Genentech, a subsidiary of Roche, granting Genentech access to MaxCyte's ExPERT GTx platform for cell therapy development. T…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.